Join us at our Capital Markets Day on Thursday, February 5, 2026, in central Stockholm and online.
The Capital Markets Day will provide investors, analysts and financial media with an update on Cereno Scientific’s clinical development program, strategic priorities and growth ambitions. The program will include presentations from the company’s management as well as contributions from external speakers with relevant scientific and clinical expertise.
Date: Thursday, February 5, 2026
Time: 13:00-16:30 CET (doors open at 12:30)
Location: GT30 Grev Ture, Grev Turegatan 30, 114 38 Stockholm
Register your participation, physical or virtual, on: https://invitepeople.com/events/ab14e4cfb5
The event will be live streamed. A recording will be available shortly after the event on the company’s website, www.cerenoscientific.com/investors/cmd-2026/.
Program
03 February 2026
Capital Markets Day 2026 program
| Time | Topic |
| 13:00 | Welcome & Opening remarks by Mike Ward, Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate (moderator) |
| 13:05 | Leadership, growth and reshaping treatment paradigms by Sten R. Sörensen, CEO at Cereno Scientific, and Mike Ward |
| 13:20 | Company progress and pipeline momentum by Sten R. Sörensen |
| 13:35 | Pulmonary arterial hypertension – disease biology, current treatments and unmet needs by Prof. Marc Humbert, Université Paris-Saclay (virtual) |
| 13:50 | Presentation: Patient perspective – living with PAH by Hall Skåra, PHA Europe |
| 14:05 | What meaningful change in therapy is desirable for patients with PAH? by Prof. Marc Humbert, Hall Skåra, Dr. Rahul Agrawal, CMO and Head of R&D at Cereno Scientific, and Mike Ward |
| 14:30 | Coffee break |
| 14:40 | Advancing CS1 into Phase IIb in PAH byDr. Rahul Agrawal |
| 14:55 | From Phase IIa to market – clinical development path for CS1 by Sten R. Sörensen, Dr. Rahul Agrawal, Dr. Björn Dahlöf, CSO at Cereno Scientific, and Mike Ward |
| 15:20 | CS1’s value proposition in the global PAH market by Sten R. Sörensen, Dr. Rahul Agrawal, Dr. Björn Dahlöf, and Mike Ward |
| 15:35 | Cereno Scientific - Strategic focus and objectives by Sten R. Sörensen |
| 15:50 | Questions from the Audience facilitated by Mike Ward |
| 16:00 | Networking and informal discussions |
Speakers
03 February 2026
External speakers
Prof. Marc Humbert
Marc Humbert, MD, PhD, is Dean and Professor of Respiratory Medicine at the Université Paris-Saclay Faculty of Medicine in Le Kremlin-Bicêtre, France. He is the Director of the Respiratory and Intensive Care Medicine Department, French Pulmonary Hypertension Reference Centre, Assistance Publique Hôpitaux de Paris and the vice-coordinator of the European Reference Network for rare and low prevalence respiratory diseases (ERN-LUNG). He heads the Inserm University Paris-Saclay Joint Research Unit UMR_S 999 (Pulmonary Hypertension: Pathophysiology and Therapeutic Innovation). Marc is Past President of the European Respiratory Society (ERS), Chief Editor of the European Respiratory Journal (2013-2017) and Section Editor in charge of Pulmonary Vascular Medicine.
Doctor Honoris Causa of the University of Medicine and Pharmacy Carol Davila (Bucarest, Romania), he has received several scientific distinctions including the 2006 ERS Cournand Lecture Award, the 2009 Descartes-Huygens Award from the Royal Netherlands Academy of Arts and Sciences, the 2016 Rare Disease Award of the Fondation de France, the 2018 ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension, the Excellence 2019 Award from the Fondation du Souffle, the 2020 American Heart Association’s 3CPR (Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation) Distinguished Achievement Award, the 2024 ERS Congress Chair Award (European Respiratory Society, Vienna), the Grand Prix of the Assistance Publique Hôpitaux de Paris Foundation (2025) and the Inserm Grand Prix (2025). Since 2018, Clarivate Analytics has listed Marc Humbert as one of the world's highly cited researchers in the field of Clinical Medicine.
Hall Skåra
Hall is a founding member and the past President of the Norwegian Pulmonary Hypertension Patient Association. He began working as a consultant for PHA Europe in 2017. One of his key responsibilities has been leading the “White Spots” program, which aims to establish new pulmonary hypertension (PH) patient associations in countries where none exist. He also provides ongoing support to these associations during their early years. The program has been highly successful, and today, only a few countries remain without a PH patient association. Hall has played a key role in developing and maintaining PHA Europe’s Bel Air Center, a virtual PH conference center. He has also been deeply involved in advocacy efforts, contributing to EU policy work, serving on scientific committees, and participating in various PH initiatives. Notably, he was part of the patient task force at the 7th World PH Symposium.
Read more: https://www.phaeurope.org/team/hall-skaara/